Femasys (FEMY) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $48M

Market Cap: $26.6MFounded: 2004HQ: Suwanee, United States

Sector Ranking#109 in Drug Delivery & Formulation

Overview

Femasys Inc. is a woman-founded, publicly-traded biomedical company on a mission to modernize the severely underserved field of women's health. The company has built a robust portfolio of in-office, non-surgical products based on a proprietary delivery platform that requires no capital equipment, aiming to improve accessibility and reduce costs. Key achievements include the commercial launch of its FemVue® diagnostic device and the advancement of its lead therapeutic candidates, FemaSeed® for infertility and FemBloc® for permanent contraception, through late-stage clinical trials. Its strategy leverages deep clinical familiarity, a strong IP portfolio of ~200 patents, and in-house manufacturing to bring transformative care directly to physicians' offices.

InfertilityContraceptionOncology Diagnostics

Technology Platform

A proprietary, non-surgical delivery platform that leverages intrauterine catheterization techniques to deliver agents to targeted sites without capital equipment, enabling in-office, minimally invasive procedures.

Funding History

3

Total raised:$48M

IPO$25MIPOJul 28, 2021

Series B$15MUndisclosedNov 15, 2019

Series A$8MUndisclosedMay 15, 2017

Opportunities

Femasys addresses massive, underserved markets in women's health with a platform aligned with the macro shift to in-office care.

Regulatory approval of FemaSeed and FemBloc could establish new standards of care in infertility and contraception, unlocking multi-billion dollar opportunities.

The company's integrated model, from in-house manufacturing to commercial sales, provides control over its destiny.

Risk Factors

The investment thesis is binary and hinges on successful FDA approval of two pivotal products via complex pathways (De Novo and PMA).

The company is pre-profitability and will likely require additional dilutive financing.

Commercial success depends on overcoming physician adoption and payer reimbursement hurdles post-approval.

Competitive Landscape

Femasys faces indirect competition from established but invasive procedures (IUI, IVF, tubal ligation) rather than direct device competitors. Its unique in-office, non-surgical platform creates a defensible niche. The discontinuation of Essure® left a clear gap in permanent contraception that FemBloc aims to fill.